Life Sciences Law360 provides breaking legal news and analysis on the pharmaceutical and medical device industry. Coverage includes high-stakes litigation and policy developments that affect life sciences companies, as well as licensing deals, mergers, and other corporate transactions.
The Eleventh Circuit has affirmed a $2.1 million jury verdict in favor of a patient who won the first bellwether trial against Wright Medical Technology over its allegedly defective metal hip implants, supporting the trial judge's decision to order the confused jury to conduct further deliberations.
The Ninth Circuit refused Tuesday to disturb California appellate precedent establishing that an excess insurance carrier must either approve a policyholder's settlement of a covered claim or assume the insured's defense if it wishes to avoid litigation, giving policyholders more leverage to secure reluctant excess insurers' participation in settlement talks.
The Florida Senate took a step Wednesday toward formulating a plan for implementing a constitutional amendment legalizing medical marijuana that passed in November, with treatment center licenses, consumption methods and qualifying conditions coming up as major issues as the Health Policy Committee reviewed multiple proposals.
U.S. drugmaker Eli Lilly has decried a recent ruling dismissing its claims brought under the North American Free Trade Agreement over Canada's controversial "promise utility doctrine" requiring patent holders to show that an invention measures up to its promised result, comments that were echoed this week by two U.S. industry groups.
A U.K. judge on Tuesday ruled that a Merck Sharp & Dohme Corp. document extending a patent on the HIV drug Atripla is invalid, in a win for generics makers Teva Pharmaceutical Industries Ltd., Mylan NV and Accord Healthcare, which challenged it.